Evidence map›Paper›PMID 42393765›Full record

ArticleActa neuropathologica communications2026

Phenotype-specific muscle proteomic profiling in titinopathies.

Aurélien Perrin, Marie-Rocio Casenave-Camgaston, Baptiste Rabillard, Fabrice Raynaud, Serge Urbach, Martial Seveno, Ana Maria Navarro, Anas Tendero-Baziou, Stephan Matecki, Claude Cancès and 23 more

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Aurélien PerrinLaboratoire de Génétique Moléculaire, Centre Hospitalier Universitaire de Montpellier, 34093, Montpellier, France. aurelien.perrin@ext.inserm.fr.ORCID https://orcid.org/0000-0001-5895-3064
Marie-Rocio Casenave-CamgastonLaboratoire de Génétique Moléculaire, Centre Hospitalier Universitaire de Montpellier, 34093, Montpellier, France.
Baptiste RabillardPhyMedExp, Université de Montpellier, INSERM, CNRS, 34093, Montpellier, France.
Fabrice RaynaudPhyMedExp, Université de Montpellier, INSERM, CNRS, 34093, Montpellier, France.
Serge UrbachIGF, University of Montpellier, CNRS, INSERM, Montpellier, France.
Martial SevenoBioCampus Montpellier, University of Montpellier, CNRS, INSERM, Montpellier, France.
Ana Maria NavarroLaboratoire de Génétique Moléculaire, Centre Hospitalier Universitaire de Montpellier, 34093, Montpellier, France.
Anas Tendero-BaziouPhyMedExp, Université de Montpellier, INSERM, CNRS, 34093, Montpellier, France.
Stephan MateckiPhyMedExp, Université de Montpellier, INSERM, CNRS, 34093, Montpellier, France.
Claude CancèsService de Neuropédiatrie, Centre de Référence des Maladies Neuromusculaires AOC (Atlantique-Occitanie-Caraïbe), Centre Hospitalier Universitaire de Toulouse, 31059, Toulouse, France.
Julien DurigneuxCentre de Référence des Maladies Neuromusculaires AOC, CHU d'Angers, Angers, France.
Valérie BiancalanaLaboratoire de Diagnostic Génétique, CHRU de Strasbourg, Strasbourg, France.
Florence PetitUniv. Lille, CHU Lille, Clinique de Génétique Guy Fontaine, Lille, France.
Céline TardService de de Neurologie A, U1172, CHU de Lille, Centre de Référence des Maladies Neuromusculaires Nord Est Ile de France, Lille, France.
Arnaud MolinNormandy University, UNICAEN, Caen University Hospital, Department of Genetics, Reference Center of Rare Diseases of Calcium and Phosphorus Metabolism, EA7450, BioTARGen, Caen, France.
Manon GodinNormandy University, UNICAEN, Caen University Hospital, Department of Genetics, Reference Center of Rare Diseases of Calcium and Phosphorus Metabolism, EA7450, BioTARGen, Caen, France.
Xénia LatypovaUniversité Grenoble Alpes, Inserm, U1216,, CHU Grenoble Alpes, Grenoble Institute of Neurosciences, 38000, Grenoble, France.
John RenduUniversité Grenoble Alpes, Inserm, U1216,, CHU Grenoble Alpes, Grenoble Institute of Neurosciences, 38000, Grenoble, France.
Médéric JeanneUMR 1253, iBrain, Université de Tours, Inserm, 37032, Tours, France.
Raul Juntas MoralesNeurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Emmanuelle Salort-CampanaReference Center for Neuromuscular Disorders and ALS, APHM, CHU La Timone, Filnemus, ERN Neuro-NMD, Marseille, France.
Annie VerschuerenReference Center for Neuromuscular Disorders and ALS, APHM, CHU La Timone, Filnemus, ERN Neuro-NMD, Marseille, France.
Martin KrahnINSERM, Marseille Medical Genetics, U1251, Aix-Marseille Université, 13385, Marseille, France.
Svetlana GorokhovaINSERM, Marseille Medical Genetics, U1251, Aix-Marseille Université, 13385, Marseille, France.
Shahram AttarianReference Center for Neuromuscular Disorders and ALS, APHM, CHU La Timone, Filnemus, ERN Neuro-NMD, Marseille, France.
Guilhem SoléCentre de Référence des Maladies Neuromusculaires AOC, Filnemus, Euro-Nmd, CHU de Bordeaux, Hôpital Pellegrin, Bordeaux, France.
Florence EsselinCentre de Référence Maladies Rares CRMR SLA CHU Montpellier, INM, Univ Montpellier, INSERM, Explorations Neurologiques, Hôpital Gui de Chauliac, Montpellier, France.
Marie-Laure Martin-NégrierLaboratoire de Pathologie, Filnemus, Euro-Nmd, CHU de Bordeaux, Hôpital Pellegrin, Bordeaux, France.
Corinne MétayAP-HP, UF Molecular Cardiogenetics and Myogenetics, Research Center in Myology, Sorbonne Université and Sorbonne Université UPMC Paris, Pitié-Salpêtrière Hospital, 06-Inserm UMRS974, Paris, France.
Christian JorgensenIRMB, Univ Montpellier, INSERM, CHU de Montpellier, Montpellier, France.
Anne BergougnouxLaboratoire de Génétique Moléculaire, Centre Hospitalier Universitaire de Montpellier, 34093, Montpellier, France.
Michel KoenigLaboratoire de Génétique Moléculaire, Centre Hospitalier Universitaire de Montpellier, 34093, Montpellier, France.
Mireille CosséeLaboratoire de Génétique Moléculaire, Centre Hospitalier Universitaire de Montpellier, 34093, Montpellier, France. mireille.cossee@inserm.fr.

Funding

AFM-Téléthon AFM 21381 - AFM 24259Association Française contre les Myopathies MYOccitanie #28589CHU de Montpellier Tremplin grantFilière Neuromusculaire FILNEMUS AAP grant
6 · The paper itself

Abstract

Titinopathies are complex neuromuscular disorders with multiple phenotypes. The gene's size, comprising 364 exons, as well as the protein's size of 3.8 MDa and its extensive network of protein interactors, are key factors underlying this complexity. Various phenotypes characterize titinopathies, and this study focuses on two of them: arthrogryposis and myofibrillar myopathies. The protein deregulations associated with these two phenotypes remain unknown or have been minimally explored; however, understanding these consequences is essential for better characterizing the pathophysiological aspects of these titinopathies.The objective was to analyze protein deregulations in two cohorts of French patients with titinopathies exhibiting the arthrogryposis and myofibrillar myopathy phenotypes, and to compare them with control individuals. Protein extracts were obtained from muscle biopsies of patients, and changes in protein levels within these two groups were analyzed by mass spectrometry. The results indicate specific deregulations in each group. The networks analyzed revealed deregulation of proteins involved in fibrosis mechanisms or in the actomyosin complex for the arthrogryposis phenotype. Regulation of the muscle contraction system through deregulation of proteins involved in the cytoskeleton is impacted in patients with myofibrillar myopathy. The proteins that are quantitatively abnormal in these two groups also provide insights into the major signaling networks disrupted in titinopathies. These findings will contribute to a more precise characterization of titinopathies, enabling the identification of phenotype-specific biomarkers and potentially guiding the search for targeted therapies for these neuromuscular disorders.

Indexed as

ArthrogryposisMuscle ProteinsMuscle, SkeletalMyopathies, Structural, CongenitalAdolescentAdultConnectinFemaleHumansMaleMiddle AgedPhenotypeProteomicsYoung AdultConnectinMuscle ProteinsMass spectrometryMyopathiesProteomicTitinopathies

Identifiers

PMID42393765
PMCPMC13602786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.